[Evaluation on the effect of Benazepril for hypertension through postmarketing surveillance]

Zhonghua Liu Xing Bing Xue Za Zhi. 2000 Jun;21(3):190-3.
[Article in Chinese]

Abstract

Objective: To evaluate the efficacy and safety of Benazepril used among the essential hypertensives.

Methods: 1 831 essential hypertensive patients aged 35 to 75 were randomly selected from a community and followed for 18 months. The level of blood pressure, status of taking Benazepril and side effects were sequencially collected.

Results: 1/3 of the patients had taken antihypertensive drug before the study and the rate of compliance was over 96%. The effective rate of Benazepril was 73.6% at three months and increased to 84.7% at 18 months. Comparing with the baseline data, SBP and DBP declined 10.8 mmHg and 6.7 mmHg respectively. The rate of side effect was 22.7%. Cough was most commonly seen among side effects. The peak of first recording on side effect occurred at three months including 60% of them mild.

Conclusion: Results showed that Benazepril had good efficacy and safety for the essential hypertension patients in a long-term observation.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Antihypertensive Agents / therapeutic use*
  • Benzazepines / adverse effects
  • Benzazepines / therapeutic use*
  • China / epidemiology
  • Cough / chemically induced
  • Female
  • Follow-Up Studies
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / epidemiology
  • Male
  • Middle Aged
  • Product Surveillance, Postmarketing

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Benzazepines
  • benazepril